出版应用/物种/样本/稀释 | 参考文献 |
---|
| Dong F, Chen M, Jiang L, Shen Z, Ma L, Han C, et al. PRMT5 Is Involved in Spermatogonial Stem Cells Maintenance by Regulating Plzf Expression via Modulation of Lysine Histone Modifications. Front Cell Dev Biol. 2021;9:673258 pubmed 出版商
|
- 免疫印迹; 人类; 1:200; 图 s9g
- ChIP-Seq; 小鼠; 图 6a
- 免疫印迹; 小鼠; 1:200; 图 s2e
| Brady N, Bagadion A, Singh R, Conteduca V, Van Emmenis L, Arceci E, et al. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nat Commun. 2021;12:3372 pubmed 出版商
|
| Kuchen E, Becker N, Claudino N, Hofer T. Hidden long-range memories of growth and cycle speed correlate cell cycles in lineage trees. elife. 2020;9: pubmed 出版商
|
| Liu P, Tee A, Milazzo G, Hannan K, Maag J, Mondal S, et al. The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35. Nat Commun. 2019;10:5026 pubmed 出版商
|
- 免疫印迹; 人类; 1:200; 图 4e, 4h
| Menon V, Thomas R, Elgueta C, Horl M, Osborn T, Hallett P, et al. Comprehensive Cell Surface Antigen Analysis Identifies Transferrin Receptor Protein-1 (CD71) as a Negative Selection Marker for Human Neuronal Cells. Stem Cells. 2019;37:1293-1306 pubmed 出版商
|
| Mooney M, Geerts D, Kort E, Bachmann A. Anti-tumor effect of sulfasalazine in neuroblastoma. Biochem Pharmacol. 2019;162:237-249 pubmed 出版商
|
- 免疫印迹基因敲除验证; 小鼠; 图 5c
- 免疫印迹; 小鼠; 图 5c
| Mirzamohammadi F, Kozlova A, Papaioannou G, Paltrinieri E, Ayturk U, Kobayashi T. Distinct molecular pathways mediate Mycn and Myc-regulated miR-17-92 microRNA action in Feingold syndrome mouse models. Nat Commun. 2018;9:1352 pubmed 出版商
|
| Otto T, Candido S, Pilarz M, Sicinska E, Bronson R, Bowden M, et al. Cell cycle-targeting microRNAs promote differentiation by enforcing cell-cycle exit. Proc Natl Acad Sci U S A. 2017;114:10660-10665 pubmed 出版商
|
- 免疫组化-石蜡切片; 人类; 1:500; 图 s9a
| van Groningen T, Koster J, Valentijn L, Zwijnenburg D, Akogul N, Hasselt N, et al. Neuroblastoma is composed of two super-enhancer-associated differentiation states. Nat Genet. 2017;49:1261-1266 pubmed 出版商
|
| Xue C, Yu D, Gherardi S, Koach J, Milazzo G, Gamble L, et al. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4. Oncotarget. 2016;7:54937-54951 pubmed 出版商
|
| Powers J, Tsanov K, Pearson D, Roels F, Spina C, EBRIGHT R, et al. Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma. Nature. 2016;535:246-51 pubmed 出版商
|
- ChIP-Seq; 人类; 图 5
- 免疫印迹; 人类; 1:1000; 图 s3
| Duffy D, Krstic A, Halasz M, Schwarzl T, Fey D, Iljin K, et al. Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma. Oncotarget. 2015;6:43182-201 pubmed 出版商
|
| Xiao D, Ren P, Su H, Yue M, Xiu R, Hu Y, et al. Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2. Oncotarget. 2015;6:40655-66 pubmed 出版商
|
- 免疫印迹; 小鼠; 图 5a
- 免疫印迹; 人类; 图 s1c
| Petroni M, Sardina F, Heil C, Sahún Roncero M, Colicchia V, Veschi V, et al. The MRN complex is transcriptionally regulated by MYCN during neural cell proliferation to control replication stress. Cell Death Differ. 2016;23:197-206 pubmed 出版商
|
- 染色质免疫沉淀
; 人类; 图 3A
- 免疫沉淀; 人类; 图 1A
- 免疫印迹; 人类; 图 1A
| Amente S, Milazzo G, Sorrentino M, Ambrosio S, Di Palo G, Lania L, et al. Lysine-specific demethylase (LSD1/KDM1A) and MYCN cooperatively repress tumor suppressor genes in neuroblastoma. Oncotarget. 2015;6:14572-83 pubmed
|
| Chen L, Rousseau R, Middleton S, Nichols G, Newell D, Lunec J, et al. Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Oncotarget. 2015;6:10207-21 pubmed
|
- 染色质免疫沉淀
; 人类
- 免疫印迹; 人类; 图 6
| Chayka O, D Acunto C, Middleton O, Arab M, Sala A. Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastic tumor cells. J Biol Chem. 2015;290:2198-212 pubmed 出版商
|
| Gustafson W, Meyerowitz J, Nekritz E, Chen J, Benes C, Charron E, et al. Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell. 2014;26:414-427 pubmed 出版商
|
| Corvetta D, Chayka O, Gherardi S, D Acunto C, Cantilena S, Valli E, et al. Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: functional and therapeutic implications. J Biol Chem. 2013;288:8332-41 pubmed 出版商
|
| Zeineldin M, Federico S, Chen X, Fan Y, Xu B, Stewart E, et al. MYCN amplification and ATRX mutations are incompatible in neuroblastoma. Nat Commun. 2020;11:913 pubmed 出版商
|
| Huang M, Tailor J, Zhen Q, Gillmor A, Miller M, Weishaupt H, et al. Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis. Cell Stem Cell. 2019;: pubmed 出版商
|
| Yin Y, Xu L, Chang Y, Zeng T, Chen X, Wang A, et al. N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway. Mol Cancer. 2019;18:11 pubmed 出版商
|
| Hald Ø, Olsen L, Gallo Oller G, Elfman L, Løkke C, Kogner P, et al. Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma. Oncogene. 2019;38:2800-2813 pubmed 出版商
|
| Chen L, Pastorino F, Berry P, Bonner J, Kirk C, Wood K, et al. Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma. Int J Cancer. 2019;144:3146-3159 pubmed 出版商
|
| Boboila S, Lopez G, Yu J, Banerjee D, Kadenhe Chiweshe A, Connolly E, et al. Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma. Oncogene. 2018;37:5451-5465 pubmed 出版商
|
| Agarwal S, Milazzo G, Rajapakshe K, Bernardi R, Chen Z, Barberi E, et al. MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma. Oncotarget. 2018;9:20323-20338 pubmed 出版商
|
| O Brien E, Selfe J, Martins A, Walters Z, Shipley J. The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells. BMC Cancer. 2018;18:217 pubmed 出版商
|
| Ferrucci F, Ciaccio R, Monticelli S, Pigini P, Di Giacomo S, Purgato S, et al. MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma. Biochim Biophys Acta Gene Regul Mech. 2018;1861:235-245 pubmed 出版商
|
| Chen L, Alexe G, Dharia N, Ross L, Iniguez A, Conway A, et al. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. J Clin Invest. 2018;128:446-462 pubmed 出版商
|
| Bosse K, Raman P, Zhu Z, Lane M, Martinez D, Heitzeneder S, et al. Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. Cancer Cell. 2017;32:295-309.e12 pubmed 出版商
|
| Dyberg C, Fransson S, Andonova T, Sveinbjörnsson B, Lännerholm Palm J, Olsen T, et al. Rho-associated kinase is a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A. 2017;114:E6603-E6612 pubmed 出版商
|
| King B, Boccalatte F, Moran Crusio K, Wolf E, Wang J, Kayembe C, et al. The ubiquitin ligase Huwe1 regulates the maintenance and lymphoid commitment of hematopoietic stem cells. Nat Immunol. 2016;17:1312-1321 pubmed 出版商
|
| Eberhardt A, Hansen J, Koster J, Lotta L, Wang S, Livingstone E, et al. Protein arginine methyltransferase 1 is a novel regulator of MYCN in neuroblastoma. Oncotarget. 2016;7:63629-63639 pubmed 出版商
|
| Murakami Tonami Y, Ikeda H, Yamagishi R, Inayoshi M, Inagaki S, Kishida S, et al. SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells. Sci Rep. 2016;6:31615 pubmed 出版商
|
| Duffy D, Krstic A, Schwarzl T, Halasz M, Iljin K, Fey D, et al. Wnt signalling is a bi-directional vulnerability of cancer cells. Oncotarget. 2016;7:60310-60331 pubmed 出版商
|
| Mandriota S, Valentijn L, Lesne L, Betts D, Marino D, Boudal Khoshbeen M, et al. Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism. Oncotarget. 2015;6:18558-76 pubmed
|
| Evans L, Chen L, Milazzo G, Gherardi S, Perini G, Willmore E, et al. SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma. Cancer Lett. 2015;363:37-45 pubmed 出版商
|
| Ambrosio S, Amente S, Napolitano G, Di Palo G, Lania L, Majello B. MYC impairs resolution of site-specific DNA double-strand breaks repair. Mutat Res. 2015;774:6-13 pubmed 出版商
|
| Izumi H, Kaneko Y. Trim32 facilitates degradation of MYCN on spindle poles and induces asymmetric cell division in human neuroblastoma cells. Cancer Res. 2014;74:5620-30 pubmed 出版商
|
| Murakami Tonami Y, Kishida S, Takeuchi I, Katou Y, Maris J, Ichikawa H, et al. Inactivation of SMC2 shows a synergistic lethal response in MYCN-amplified neuroblastoma cells. Cell Cycle. 2014;13:1115-31 pubmed 出版商
|
| Lodrini M, Oehme I, Schroeder C, Milde T, Schier M, Kopp Schneider A, et al. MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. Nucleic Acids Res. 2013;41:6018-33 pubmed 出版商
|
| Watters K, Bryan K, Foley N, Meehan M, Stallings R. Expressional alterations in functional ultra-conserved non-coding RNAs in response to all-trans retinoic acid--induced differentiation in neuroblastoma cells. BMC Cancer. 2013;13:184 pubmed 出版商
|
| Valli E, Trazzi S, Fuchs C, Erriquez D, Bartesaghi R, Perini G, et al. CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells. Biochim Biophys Acta. 2012;1819:1173-85 pubmed 出版商
|
| Tivnan A, Orr W, Gubala V, Nooney R, Williams D, McDonagh C, et al. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS ONE. 2012;7:e38129 pubmed 出版商
|
| Varlakhanova N, Cotterman R, Bradnam K, Korf I, Knoepfler P. Myc and Miz-1 have coordinate genomic functions including targeting Hox genes in human embryonic stem cells. Epigenetics Chromatin. 2011;4:20 pubmed 出版商
|
| Murphy D, Buckley P, Bryan K, Watters K, Koster J, van Sluis P, et al. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis. Mol Carcinog. 2011;50:403-11 pubmed 出版商
|
| Iraci N, Diolaiti D, Papa A, Porro A, Valli E, Gherardi S, et al. A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF. Cancer Res. 2011;71:404-12 pubmed 出版商
|
| Muth D, Ghazaryan S, Eckerle I, Beckett E, Pöhler C, Batzler J, et al. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma. Cancer Res. 2010;70:3791-802 pubmed 出版商
|
| Veas Perez de Tudela M, Delgado Esteban M, Cuende J, Bolanos J, Almeida A. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase. J Neurochem. 2010;113:819-25 pubmed 出版商
|
| Murphy D, Buckley P, Bryan K, Das S, Alcock L, Foley N, et al. Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation. PLoS ONE. 2009;4:e8154 pubmed 出版商
|
| Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009;10:R64 pubmed 出版商
|
| Westermann F, Muth D, Benner A, Bauer T, Henrich K, Oberthuer A, et al. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol. 2008;9:R150 pubmed 出版商
|